TY - CHAP
T1 - Selenocystine and cancer
AU - Misra, Sougat
AU - Björnstedt, Mikael
N1 - Funding Information:
The authors would like to thank financial support from Barncancerfonden, Cancerfonden, Cancer-och Allergifonden, KI Fonder, Jochnick Foundation, Radiumhemmetsforsknings fonder, and the County Council of Stockholm.
Funding Information:
Acknowledgments The authors would like to thank financial support from Barncancerfonden, Cancerfonden, Cancer-och Allergifonden, KI Fonder, Jochnick Foundation, Radiumhemmetsforsknings fonder, and the County Council of Stockholm.
Publisher Copyright:
© Springer International Publishing AG, part of Springer Nature 2018.
PY - 2018
Y1 - 2018
N2 - The diselenide compound selenocystine is a selenium analog of cystine. It is more reactive compared to cystine due to intrinsic differences in chemical properties between sulfur and selenium. Thioredoxin reductase or excess cysteine and glutathione reduces selenocystine to highly reactive selenolate. When selenocystine is present at high concentration, selenolate-mediated biochemical reactions perturb cellular redox homeostasis and induce oxidative stress. Limited pharmacokinetic studies indicate rather long half-life and biphasic elimination kinetics of selenocystine. It is well tolerated in mice and rats with a narrow window between no observed effects and toxicity. Several preclinical studies have interrogated its redox modulatory effects as an anticancer modality. Reported cytotoxic effects include DNA damage, S-phase arrest, activation of P53, alteration of MAPK and PI3K-AKT signaling pathways, loss of mitochondrial membrane potential, and release of cytochrome C. So far, findings from published studies suggest limited antineoplastic effects of selenocystine in various animal models of cancer.
AB - The diselenide compound selenocystine is a selenium analog of cystine. It is more reactive compared to cystine due to intrinsic differences in chemical properties between sulfur and selenium. Thioredoxin reductase or excess cysteine and glutathione reduces selenocystine to highly reactive selenolate. When selenocystine is present at high concentration, selenolate-mediated biochemical reactions perturb cellular redox homeostasis and induce oxidative stress. Limited pharmacokinetic studies indicate rather long half-life and biphasic elimination kinetics of selenocystine. It is well tolerated in mice and rats with a narrow window between no observed effects and toxicity. Several preclinical studies have interrogated its redox modulatory effects as an anticancer modality. Reported cytotoxic effects include DNA damage, S-phase arrest, activation of P53, alteration of MAPK and PI3K-AKT signaling pathways, loss of mitochondrial membrane potential, and release of cytochrome C. So far, findings from published studies suggest limited antineoplastic effects of selenocystine in various animal models of cancer.
UR - http://www.scopus.com/inward/record.url?scp=85091485196&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85091485196&partnerID=8YFLogxK
U2 - 10.1007/978-3-319-95390-8_14
DO - 10.1007/978-3-319-95390-8_14
M3 - Chapter
AN - SCOPUS:85091485196
T3 - Molecular and Integrative Toxicology
SP - 271
EP - 286
BT - Molecular and Integrative Toxicology
PB - Springer Science+Business Media B.V.
ER -
